Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...

In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...

On January 27 and 28, Bhatt sold a total of 3,273 shares at an average price ... stock, the company appears slightly undervalued based on its Fair Value analysis. In other recent news, Supernus ...

If you buy and hold a stock for many years ... Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals, ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus ...